Simulations to assess phase II noninferiority trials of different doses of capecitabine in combination with docetaxel for metastatic breast cancer

CPT: Pharmacometrics and Systems Pharmacology

Volumn 1, Issue 1, 2012, Pages

  Bruno, R ^a   Lindbom, L ^a   Schaedeli Stark, F ^b   Chanu, P ^a   Gilberg, F ^c   Frey, N ^b   Claret, L ^a  

^a CERTARA   (United States)

^b Clinical Modeling and Simulation Translational Research Sciences   (Switzerland)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DOCETAXEL;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

EID: 84881212890     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2012.20     Document Type: Article

References (20)

1. Budman, D.R. et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine. J. Clin. Oncol. 16, 1795-1802 (1998
2. Reigner, B., Blesch, K. & Weidekamm, E. Clinical pharmacokinetics of capecitabine. Clin. Pharmacokinet. 40, 85-104 (2001
3. O'Shaughnessy, J. et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J. Clin. Oncol. 20, 2812-2823 (2002
4. Buzdar, A.U. et al. Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer. Ann. Oncol. 23, 589-597 (2012
5. Claret, L. et al. Model-based predictions of expected anti-tumor response and survival in phase III studies based on phase II data of an investigational agent. J. Clin. Oncol. 24, 307s (2006
6. Claret, L. et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J. Clin. Oncol. 27, 4103-4108 (2009
7. Kimko, H.C. & Peck, C.C. eds. Clinical Trial Simulations: Applications and Trends. AAPS Advances in the Pharmaceutical Sciences Series. Vol. 1. (Springer, New York, 2011
8. Gieschke, R., Reigner, B.G. & Steimer, J.L. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling. Int. J. Clin. Pharmacol. Ther. 35, 469-474 (1997
9. Veyrat-Follet, C., Bruno, R., Olivares, R., Rhodes, G.R. & Chaikin, P. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin. Pharmacol. Ther. 68, 677-687 (2000
10. Wang, Y. et al. Elucidation of relationship between tumor size and survival in non-smallcell lung cancer patients can aid early decision making in clinical drug development. Clin. Pharmacol. Ther. 86, 167-174 (2009
11. Claret, L., Lu, J.F., Sun, Y.N. & Bruno, R. Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer. Cancer Chemother. Pharmacol. 66, 1141-1149 (2010
12. Lindbom, L., Claret, L., Andre, V., Cleverly, A., de Alwis, D. & Bruno, R. A drug independent tumor size reduction-survival model in advanced ovarian cancer to support early clinical development decisions. . 2009. Accessed 3 June 2011.
13. Bruno, R. et al. Simulation of clinical outcome for pomalidomide plus low-dose dexamethasone in patients with refractory multiple myeloma based on week 8 M-protein response. Blood 118, 1881 (Abstract) (2011
14. Karrison, T.G., Maitland, M.L., Stadler, W.M. & Ratain, M.J. Design of phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non small-cell lung cancer. J. Natl. Cancer Inst. 99, 1455-1461 (2007
15. Bruno, R. & Claret, L. On the use of change in tumor size to predict survival in clinical oncology studies: Toward a new paradigm to design and evaluate phase II studies. Clin. Pharmacol. Ther. 86, 136-138 (2009
16. Zielinski, C., Gralow, J. & Martin, M. Optimising the dose of capecitabine in metastatic breast cancer: Confused, clarified or confirmed? Ann. Oncol. 21, 2145-2152 (2010
17. Hénin, E. et al. A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. Clin. Pharmacol. Ther. 85, 418-425 (2009
18. Claret, L., Lu, J.F., Bruno, R., Hsu, C.P., Hei, H.J., & Sun, Y.N. Simulations using a public domain drug-disease modeling framework and Phase II data predict Phase III survival outcome in first-line non-small-cell lung cancer (NSCLC). Clin. Pharmacol. Ther. 92, 631-634 (2012
19. World Health Organization. Handbook for Reporting Results of Cancer Treatment. (World Health Organization, Geneva, Switzerland, 1979
20. Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205-216 (2000